{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:35:08Z","timestamp":1793781308659,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.radonc.2025.111041","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:55:52Z","timestamp":1752580552000},"page":"111041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial"],"prefix":"10.1016","volume":"210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2691-3505","authenticated-orcid":false,"given":"Kara M.","family":"Ruicci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-669X","authenticated-orcid":false,"given":"Aisling","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-6974","authenticated-orcid":false,"given":"Xiang Y.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Catton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruz","family":"Mesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McPartlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0254","authenticated-orcid":false,"given":"Jeff","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6121-637X","authenticated-orcid":false,"given":"Jennifer","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Fallah-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikaash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-2292","authenticated-orcid":false,"given":"Di Maria","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikala","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Helou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Glicksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10162","key":"10.1016\/j.radonc.2025.111041_b0005","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.radonc.2025.111041_b0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.radonc.2025.111041_b0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.radonc.2025.111041_b0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.radonc.2025.111041_b0025","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease volume and Risk Subgroups in the Phase III ARASENS Trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10336","key":"10.1016\/j.radonc.2025.111041_b0030","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.radonc.2025.111041_b0035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","article-title":"Development and prevalence of castration-resistant prostate cancer subtypes","volume":"22","author":"Vellky","year":"2020","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.radonc.2025.111041_b0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.radonc.2025.111041_b0045","article-title":"Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer","volume":"10","author":"Sathianathen","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.radonc.2025.111041_b0050","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The Dandelion Dilemma Revisited for Oligoprogression: Treat the whole Lawn or Weed Selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"2","key":"10.1016\/j.radonc.2025.111041_b0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41416-021-01319-8","article-title":"Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework","volume":"125","author":"Saini","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.radonc.2025.111041_b0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.radonc.2025.111041_b0065","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.semradonc.2023.07.001","article-title":"Advances and challenges in Trials of Local Therapy for patients with Oligometastatic or Oligoprogressive Disease","volume":"33","author":"Yan","year":"2023","journal-title":"Semin. Radiat. Oncol."},{"issue":"10422","key":"10.1016\/j.radonc.2025.111041_b0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.radonc.2025.111041_b0075","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3892\/ol.2016.5540","article-title":"Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: a novel approach to extend chemotherapy efficacy","volume":"13","author":"Wray","year":"2017","journal-title":"Oncol. Lett."},{"issue":"10185","key":"10.1016\/j.radonc.2025.111041_b0080","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.radonc.2025.111041_b0085","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11547-021-01424-x","article-title":"Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis","volume":"127","author":"Valeriani","year":"2022","journal-title":"Radiol. Med."},{"key":"10.1016\/j.radonc.2025.111041_b0090","article-title":"The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From A Phase 2 Nonrandomized Controlled Trial","author":"Glicksman","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.radonc.2025.111041_b0095","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncolo Biol Phys"},{"issue":"12","key":"10.1016\/j.radonc.2025.111041_b0100","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s00345-019-02717-7","article-title":"Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study","volume":"37","author":"Triggiani","year":"2019","journal-title":"World J. Urol."},{"issue":"3","key":"10.1016\/j.radonc.2025.111041_b0105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euo.2020.05.004","article-title":"Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer","volume":"4","author":"Deek","year":"2021","journal-title":"European Urology Oncology"},{"issue":"2","key":"10.1016\/j.radonc.2025.111041_b0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.euo.2019.08.012","article-title":"Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer","volume":"4","author":"Berghen","year":"2021","journal-title":"European Urology Oncology"},{"issue":"5","key":"10.1016\/j.radonc.2025.111041_b0115","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: the ORIOLE phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.radonc.2025.111041_b0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: a Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.radonc.2025.111041_b0125","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: the EXTEND Phase 2 Randomized Clinical Trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.radonc.2025.111041_b0130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.clon.2024.06.047","article-title":"Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial","volume":"36","author":"Patel","year":"2024","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"6","key":"10.1016\/j.radonc.2025.111041_b0135","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.euo.2024.04.003","article-title":"Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results From The Prospective, Single-Arm, Phase 2 MEDCARE Trial","volume":"7","author":"Rans","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"36","key":"10.1016\/j.radonc.2025.111041_b0140","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic Body Radiation Therapy and Abiraterone Acetate for patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: a Randomized Phase II Trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.radonc.2025.111041_b0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.2025.43.5_suppl.22","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: a randomized phase II trial (GROUQ-PCS 9)","volume":"43","author":"Niazi","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.radonc.2025.111041_b0150","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.prro.2024.04.022","article-title":"A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)","volume":"14","author":"Conde-Moreno","year":"2024","journal-title":"Pract. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.radonc.2025.111041_b0155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12885-020-06853-x","article-title":"Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial","volume":"20","author":"Berghen","year":"2020","journal-title":"BMC Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:27:09Z","timestamp":1789172829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025045451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"alternative-id":["S0167814025045451"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111041","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111041"}}